中国神经再生研究(英文版) ›› 2023, Vol. 18 ›› Issue (2): 293-298.doi: 10.4103/1673-5374.346487

• 综述:退行性病与再生 • 上一篇    下一篇

Mortalin/Hspa9 在帕金森病中的参与和治疗前景

  

  • 出版日期:2023-02-15 发布日期:2022-08-05

Mortalin/Hspa9 involvement and therapeutic perspective in Parkinson’s disease

Baptiste Texier1, #, Morgane Prime1, #, Djamaa Atamena2, #, Pascale Belenguer2, Marion Szelechowski1, *   

  1. 1Toulouse Institute for Infectious and Inflammatory Diseases (INFINITY), Université Toulouse, CNRS, Inserm, UPS, Toulouse, France; 2Centre de Recherches sur la Cognition Animale (CRCA), Centre de Biologie Intégrative (CBI), Université de Toulouse, CNRS, UPS, Toulouse, France
  • Online:2023-02-15 Published:2022-08-05
  • Contact: Marion Szelechowski, PhD, marion.szelechowski@inserm.fr.

摘要: https://orcid.org/0000-0002-2929-7413 (Marion Szelechowski)

Abstract: By controlling the proper folding of proteins imported into mitochondria and ensuring crosstalk between the reticulum and mitochondria to modulate intracellular calcium fluxes, Mortalin is a chaperone protein that plays crucial roles in neuronal homeostasis and activity. However, its expression and stability are strongly modified in response to cellular stresses, in particular upon altered oxidative conditions during neurodegeneration. Here, we report and discuss the abundant literature that has highlighted its contribution to the pathophysiology of Parkinson’s disease, as well as its therapeutic and prognostic potential in this still incurable pathology.

Key words: chaperone, Hspa9, mitochondria, Mortalin, neurodegeneration, oxidative stress, Parkinson’s disease, prognostic and therapeutic potential